What Do Published Reports Reveal About Reglan and Tardive Dyskinesia?

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Information to Occupational Exposure Concerns

If you or a loved one has taken Reglan and noticed involuntary muscle movements, you may be concerned about tardive dyskinesia. This neurological condition has been documented in medical literature for decades, with research linking long-term use of metoclopramide to persistent movement disorders. This page reviews published reports and FDA labeling to clarify clinical red flags and what they mean for patients.

Reglan and Tardive Dyskinesia: Medical Evidence and FDA Warnings

Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis. The FDA-approved labeling explicitly states that Reglan can cause tardive dyskinesia (TD), a potentially irreversible movement disorder characterized by involuntary, often disfiguring movements of the face, tongue, trunk, or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For gastroesophageal reflux, the maximum approved treatment duration is 12 weeks; for diabetic gastroparesis, use beyond 12 weeks should be avoided, and if longer-term use is unavoidable, patients must be routinely monitored for TD signs (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the drug should be discontinued immediately if signs or symptoms of TD appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The clinical presentation of TD includes involuntary, repetitive movements such as lip smacking, tongue protrusion, grimacing, and rapid eye blinking. These movements can be disfiguring and may persist even after Reglan is stopped. The FDA label notes that metoclopramide may suppress or partially suppress TD signs, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves dopamine receptor blockade in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent involuntary movements. This effect is dose- and duration-dependent, with longer exposure increasing the likelihood of irreversible damage.

Statute of Limitations for Reglan Claims in Pennsylvania

For patients in Pennsylvania considering legal action related to Reglan-induced TD, the statute of limitations is a critical factor. Pennsylvania law generally requires personal injury claims to be filed within two years of the date the injury was discovered or reasonably should have been discovered. For TD, this timeline can be complex because symptoms may develop gradually and may not be immediately recognized as drug-related. The FDA label warns that TD can occur after short-term use, but risk increases with longer treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who took Reglan for more than 12 weeks, especially for off-label or prolonged use, may have a stronger basis for a claim if they were not adequately warned of the TD risk. Settlement considerations for affected patients hinge on several factors. First, the adequacy of warnings is central: the FDA boxed warning clearly states the risk of TD, but patients may argue that their prescribing physician did not communicate this risk or that the warning was insufficient given the drug's widespread use for conditions like gastroparesis. Second, the timeline between exposure and documented harm matters. Patients who developed TD after short-term use (e.g., less than 12 weeks) may have a different risk profile than those who used Reglan for months or years. Third, the severity and irreversibility of TD can influence settlement amounts, as the condition can cause permanent disability, social stigma, and loss of quality of life. In Pennsylvania, the statute of limitations clock typically starts when the patient knew or should have known that TD was caused by Reglan. This may be triggered by a formal diagnosis from a neurologist or by the patient's own recognition of symptoms. Because TD can be mistaken for other movement disorders, patients may not connect their symptoms to Reglan until years after exposure. Courts may apply the 'discovery rule,' which allows the statute to begin when the injury is discovered, not when the drug was taken. However, patients should not delay seeking legal advice, as delays can jeopardize their ability to file a claim.

Settlement Factors and Legal Considerations

For those considering a settlement, it is important to document all medical records showing Reglan prescriptions, duration of use, and any diagnoses of TD. Evidence of inadequate warnings—such as a lack of discussion about TD risk during prescribing—can strengthen a claim. The FDA label explicitly states that Reglan is not recommended for pediatric patients due to TD risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397), and this may be relevant for cases involving off-label pediatric use. In summary, patients in Pennsylvania who developed TD after taking Reglan should be aware of the two-year statute of limitations from the date of discovery of the injury. The FDA's boxed warning provides clear evidence of the drug's known risks, and the duration of use is a key factor in assessing liability. Settlement amounts will depend on the severity of TD, the adequacy of warnings, and the timeline between exposure and diagnosis. Patients should consult with a legal professional experienced in pharmaceutical litigation to evaluate their specific case and ensure timely filing.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in Pennsylvania?

In Pennsylvania, personal injury claims generally must be filed within two years from the date the injury was discovered or reasonably should have been discovered. For tardive dyskinesia caused by Reglan, this clock typically starts when the patient knew or should have known that TD was linked to the drug, such as upon a formal diagnosis. Courts may apply the 'discovery rule' to allow filing later if the connection was not immediately apparent.

How does the FDA label address the risk of tardive dyskinesia with Reglan?

The FDA-approved labeling for Reglan includes a boxed warning stating that metoclopramide can cause tardive dyskinesia, a potentially irreversible movement disorder. The risk increases with longer treatment duration and higher cumulative doses. The label advises that use beyond 12 weeks should be avoided for most indications and that the drug should be discontinued if TD signs appear (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.